ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "glucocorticoids"

  • Abstract Number: 1010 • ACR Convergence 2025

    Confounding by Indication in Observational Studies Investigating Glucocorticoid-Associated Adverse Events in Patients with Rheumatoid Arthritis: A Systematic Literature Review

    Andriko Palmowski1, Anne Elisabeth Beenken2, Anne Pankow2, Judith Oldenkott2, Henriette Käding2, Edgar Wiebe3, Zhivana Boyadzhieva4, Eric L Matteson5, Ioanna Minopoulou6, Thorben Witte2, David Simon7, Arnd Kleyer6 and FRANK BUTTGEREIT8, 1Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 2Charité, Berlin, Germany, 3Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Berlin, Germany, 4Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Berlin, Germany, 5Mayo Clinic College of Medicine and Science, Rochester, MN, 6Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany, 7Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Germany, 8Charité University Medicine Berlin, Berlin, Berlin, Germany

    Background/Purpose: Observational studies investigating glucocorticoids (GCs) and related adverse events (AEs) in patients with rheumatoid arthritis (RA) can suffer from bias by indication if confounders…
  • Abstract Number: 0372 • ACR Convergence 2025

    Development and Implementation of a Remote Educational Program to Optimize Safe Medication Use in Older Veterans with Rheumatic Diseases

    Maria Romero Noboa1, Hannah Howell2, Angelo Gaffo3 and Maria I. ("Maio") Danila4, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, 3Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL, USA; Birmingham VA Medical Center, Birmingham, AL, USA, Birmingham, AL, 4University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL

    Background/Purpose: Symptomatic treatment in rheumatic and musculoskeletal diseases (RMDs) – including glucocorticoids (GCs) and non-steroidal anti-inflammatory drugs (NSAIDs) – can result in improved quality of…
  • Abstract Number: 1671 • ACR Convergence 2025

    Emapalumab Treatment for Patients with Differing Presentations of Macrophage Activation Syndrome (MAS) Secondary to Still’s Disease: Results from a Pooled Analysis of Two Prospective Trials

    Alexiei GROM1, Sebastiaan Vastert2, Jordi anton3, Pierre Quartier4, Bruno Fautrel5, Paul Brogan6, Edward Behrens7, Melissa Elder8, Francesca Minoia9, Pavla Dolezalova10, Robert Biesen11, Masaki Shimizu12, Uwe Ullmann13, Adnan Mahmood14, Andrew Danquah13, Elena Burillo13, Marco Petrimpol13, Steve Mallett15, Brian Jamieson16 and Fabrizio De Benedetti17, 1Cincinnati Children’s Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, 2University Medical Center Utrecht, Utrecht, Utrecht, Netherlands, 3Hospital Sant Joan de Düu. Universitat de Barcelona, Barcelona, Spain, 4Hôpital Necker-Enfants Malades, Paris, France, 5Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS 1136-5, PARIS, France, Paris, France, 6Great Ormond Street Hospital for Children NHS Foundation Trust and University College London Great Ormond Street Institute of Child Health, London, United Kingdom, 7CHOP, West Chester, PA, 8College of Medicine and Division of Pediatric Allergy, Immunology, and Rheumatology, Department of Pediatrics, University of Florida, GAINESVILLE, FL, 9Pediatric Immuno-Rheumatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy, 10Paediatric Rheumatology and Autoinflammatory Diseases Unit, General University Hospital, Prague, Czech Republic, 11Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany, 12Department of Pediatrics and Developmental Biology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, 13Sobi, Basel, Switzerland, 14Sobi, Stockholm, Sweden, 15Sobi, Stock, Sweden, 16Sobi Inc., Morrisville, NC, 17Bambino Gesu Children's Hospital, Rome, Rome, Italy

    Background/Purpose: MAS is a life-threatening complication of Still’s disease characterized by systemic IFNg-driven hyperinflammation. Patients with Still’s disease may present with MAS at any disease…
  • Abstract Number: 0895 • ACR Convergence 2025

    Impact of Glucocorticoid Tapering in Giant Cell Arteritis: Analysis From the SELECT-GCA Trial

    FRANK BUTTGEREIT1, Kevin Winthrop2, Leonard Calabrese3, Ivan Lagunes4, Aditi Kadakia5, Ana Romero6, Shaofei Zhao4, Weihan Zhao4, Arathi Setty4 and Jeffrey Curtis7, 1Charité University Medicine Berlin, Berlin, Berlin, Germany, 2Oregon Health & Science University, Portland, OR, 3Cleveland Clinic, Cleveland, OH, 4Abbvie Inc, North Chicago, IL, 5AbbVie Inc, Woburn, MA, 6AbbVie, Barcelona, Spain, 7University of Alabama at Birmingham, Birmingham

    Background/Purpose: This study assessed the occurrence of adverse events of serious infections, herpes zoster, and opportunistic infection during concomitant treatment with GCs and after GC…
  • Abstract Number: 0360 • ACR Convergence 2025

    Assessing Content Validity of a New Questionnaire Evaluating Glucocorticoid Toxicity

    Timothy Howell1, anne Skalicky2, Louis Matza1, John Stone3, Martha Stone4, Vijayaraghava Rao5 and Glenn Phillips5, 1evidera, Washington, DC, 2evidera, Seattle, WA, 3Massachusetts General Hospital , Harvard Medical School, Concord, MA, 4Steritas, LLC, Concord, MA, 5argenx, Boston, MA

    Background/Purpose: While glucocorticoids (GCs) are commonly used to treat a range of inflammatory diseases, the burden of toxicities associated with these medications is significant. The…
  • Abstract Number: 1629 • ACR Convergence 2025

    Real-World Effectiveness of Interleukin-6 Receptor Inhibitors Compared to Methotrexate in Steroid-Refractory Frail Patients with Polymyalgia Rheumatica

    Sebastian E Sattui1, Christian Dejaco2, Kerri Ford3, Stefano Fiore4, Sebastian H Unizony5, Fenglong Xie6 and Jeffrey Curtis7, 1Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 2Medical University of Graz, Department of Rheumatology, Graz, Austria; Department of Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy, 3Sanofi, Cambridge, MA, 4Sanofi, Morristown, NJ, 5Massachusetts General Hospital, Harvard Medical School, Boston, MA, 6The University of Alabama at Birmingham, Birmingham, AL, 7Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL

    Background/Purpose: A previous post hoc analysis of frail (defined by claims-based frailty index [CFI] ≥0.2) patients with PMR on second line (2L) and 3L treatment…
  • Abstract Number: 0668 • ACR Convergence 2025

    Glucocorticoid-Sparing Effects and Flare Suppression: Metformin Versus SGLT2 Inhibitors in Systemic Lupus Erythematosus

    Takeshi Suzuki, Yoshiki Ishizaki, Takayasu Ando, Shotaro Suzuki, Keiichi Sakurai, Kumiko Tonooka, Yukiko Takakuwa, Hiroko Nagafuchi, Seido Ooka and Kimito Kawahata, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan

    Background/Purpose: While both metformin (MET) and SGLT2 inhibitors (SGLT2i) have potential immunomodulatory effects in Systemic Lupus Erythematosus (SLE), their comparative efficacy in glucocorticoid (GC)-sparing remains…
  • Abstract Number: 0349 • ACR Convergence 2025

    Underrecognized Glucocorticoid-Induced Osteoporosis in a Polymyalgia Rheumatica Patient Cohort

    katherine Loomba1, Emily Campbell1, Nisha Khubchandani1, chih Fang1, William Rigby2 and Vivekanand Tiwari1, 1Dartmouth Hitchcock Medical Center, Lebanon, NH, 2Dartmouth-Hitchcock, Norwich, VT

    Background/Purpose: Polymyalgia Rheumatica (PMR) and Giant Cell Arteritis (GCA) are systemic inflammatory disorders treated with prolonged corticosteroid therapy. Prolonged use of corticosteroids is a significant…
  • Abstract Number: 0774 • ACR Convergence 2024

    A Multicenter, Randomized, Controlled Trial to Evaluate the Effects of Low-dose Glucocorticoids Compared to Stopping Glucocorticoids to Maintain Remission of Granulomatosis with Polyangiitis: The TAPIR Trial

    Peter Merkel1, Christian Pagnoux2, Nader Khalidi3, Ulrich Specks4, Curry Koening5, Carol Langford6, Larry Moreland7, Paul Monach8, Jason Springer9, Shubhasree Banerjee1, Simon Carette10, Rennie Rhee1, Medha Soowamber11, Kenneth Warrington4, Renee Borchin12, Cristina Burroughs13, Carol McAlear1, David Cuthbertson13 and Jeffrey Krischer13, 1University of Pennsylvania, Philadelphia, PA, 2Mount Sinai Hospital, Toronto, ON, Canada, 3McMaster University, Hamilton, ON, Canada, 4Mayo Clinic, Rochester, MN, 5University of Texas Dell Medical School, Austin, TX, 6Cleveland Clinic, Moreland Hills, OH, 7University of Colorado, Denver, CO, 8VA Boston Healthcare System, Boston, MA, 9Vanderbilt University Medical Center, Franklin, TN, 10Mount Sinai Hosptial, Toronto, ON, Canada, 11University of Toronto, Toronto, ON, Canada, 12University of South Florida, Tampa, 13University of South Florida, Tampa, FL

    Background/Purpose: Use of low-dose glucocorticoids to maintain remission in patients with granulomatosis with polyangiitis (GPA) remains controversial.  Additionally, there is no consensus on how to…
  • Abstract Number: 1695 • ACR Convergence 2024

    Efficacy of Upadacitinib in Patients with Giant Cell Arteritis: Subgroup Analysis of the SELECT-GCA Phase 3 Trial

    Peter Merkel1, Arathi Setty2, Ricardo Blanco-Alonso3, Ravi Suppiah4, Thomas Daikeler5, Valerie Devauchelle6, Elisabeth Brouwer7, Hiromichi Tamaki8, Liu Meng2, Yang Yang2, Avani Joshi2, Charles Phillips2, Peter K. Wung2 and Cristina Ponte9, 1Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, 2AbbVie, North Chicago, IL, 3Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, 4Health New Zealand, Te Toka Tumai Auckland, Auckland, New Zealand, 5university hospital, Basel, Switzerland, 6UBO, Brest, France, 7University Medical Center Groningen, Groningen, Netherlands, 8St. Luke's International Hospital, Tokyo, Japan, 9Unidade Local de Saúde Santa Maria, Serviço de Reumatologia e Doenças Ósseas Metabólicas, Lisboa, Portugal., Lisbon, Portugal

    Background/Purpose: Giant cell arteritis (GCA) is a chronic systemic vasculitis with limited targeted therapeutic options. The recent SELECT-GCA phase 3 trial demonstrated a favorable benefit-risk…
  • Abstract Number: 2419 • ACR Convergence 2024

    Clinical and Patient-reported Outcomes in Systemic Lupus Erythematosus: An Analysis of the SLE Prospective Observational Cohort Study (SPOCS) US Data

    Richard Furie1, Mawuena Binka2, Gelareh Atefi3, Stephanie Y. Chen4 and Bo Ding5, 1Northwell Health, Manhasset, NY, 2BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, 3AstraZeneca, Media, PA, 4BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, 5BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden

    Background/Purpose: SLE is an autoimmune disease with diverse manifestations and progression patterns that, via disease activity and effects of standard therapy, imposes a significant burden…
  • Abstract Number: 2648 • ACR Convergence 2024

    Diagnosis of Giant Cell Arteritis by 18F-FDG PET/CT in Patients on Glucocorticoid Therapy: Importance of Delayed Imaging

    Vicente Aldasoro1, Vicky Betech-Antar2, Santos Castañeda3, Eugenio De Miguel4, Juan José Rosales5 and Maria Jose García Velloso5, 1Hospital Universitario de Navarra, Pamplona, Spain, 2Clinica Universidad de Navarra, Pamplona, Spain, 3Hospital Universitario de la Princesa, Madrid, Spain, 4Hospital Universitario La Paz, Madrid, Spain, 5Clínica Universidad de Navarra, Pamplona, Spain

    Background/Purpose: The aim of this study is to analyse the diagnostic value of the delay images at 180 minutes in positron emission tomography (PET) performed in…
  • Abstract Number: 0858 • ACR Convergence 2024

    Baricitinib in Early Polymyalgia Rheumatica (BACHELOR Study)

    Alain SARAUX1, Guillermo CARVAJAL ALEGRIA2, Emmanuelle Dernis3, christian roux4, Christophe Richez5, Alice TISON6, Baptiste Quere7, Sandrine Jousse-Joulin8, Dewi Guellec7, Thierry Marhadou9, Patrice Kervarrec7, Divi Cornec10, Catherine Le Henaff7, Sandra Lesven7, nowak emmanuel7, Aghiles Souki7 and Valerie Devauchelle11, 1CHU Brest, Brest, France, 2CHRU de Tours, Tours, France, 3CH LE MANS, LE MANS, Pays de la Loire, France, 4rheumatology department, university Cote d'Azur, nice, France, 5Université de Bordeaux, Bordeaux, France, 6CHU de la Cavale Blanche, Brest, France, Brest, France, 7Centre Hospitalier Regional Universitaire (CHU) de Brest, Brest, France, 8cavale blanche hospital, brest, France, 9CHU Cavale Blanche, Brest, France, 10University of Brest, Brest, France, 11UBO, Brest, France

    Background/Purpose: Moderate glucocorticoids (GCs) improve nearly all cases of polymyalgia rheumatica (PMR) but related adverse events are common in senior patients.  The purpose of this…
  • Abstract Number: 1700 • ACR Convergence 2024

    Comparative Effectiveness of Sarilumab vs. Methotrexate as a Glucocorticoid-Sparing Agent in Patients with Polymyalgia Rheumatica

    Jeffrey Curtis1, Fenglong Xie2, Shanette Daigle3 and Sebastian E. Sattui4, 1The University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3FASTER, Birmingham, AL, 4University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Polymyalgia rheumatica (PMR) is an inflammatory condition that typically affects older individuals for whom long term glucocorticoid (GC) use may be undesirable. Moreover, the…
  • Abstract Number: 2421 • ACR Convergence 2024

    Trends in Glucocorticoid Use in Systemic Lupus Erythematosus in a Population-Based Inception Cohort from 1976 to 2018: The Lupus Midwest Network

    Mariana Gonzalez-Trevino1, Jaime Flores Gouyonnet1, Qiping Xu2, Cassondra Hulshizer3, Jose Meade-Aguilar4, Erika Navarro-Mendoza1, Mario Bautista-Vargas5, Gabriel Figueroa-Parra6, Alain Sanchez-Rodriguez7, Maria Cuellar-Gutierrez1, Andrew C. Hanson8, Cynthia Crowson1 and Ali Duarte-Garcia1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic Health System - Mankato, Mankato, MN, 3Mayo Clinic, Utica, MN, 4Boston University/Boston Medical Center, Boston, MA, 5Mayo Clinic, Rochester, Minnesota, USA., Rochester, MN, 6Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 7Mayo Clinic College of Medicine and Science, Rochester, MN, 8Mayo Clinic, Rochester

    Background/Purpose: We examined the patterns of glucocorticoid (GC) use and the temporal trends of GC initiation, discontinuation, and reduction over four decades in a population-based…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 25
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology